Pakistani diabetes medicines match multinational brands: experts
LAHORE: In Pakistan, where millions of families struggle to make both ends meet and cannot afford costly treatment, a local study found that Pakistani biosimilar medicines deliver diabetes control and weight loss comparable to their multinational counterparts. The findings were presented at the concluding day of PESCON 2026, the Pakistan Endocrine Society’s 24th annual conference. Medical experts…
A recent study conducted in Pakistan has found that local biosimilar medicines for diabetes control and weight loss deliver comparable results to their multinational counterparts, according to experts at the Pakistan Endocrine Society’s 24th annual conference. The research, presented by consultant endocrinologist Dr Nauman Niaz, revealed that the local medicine costs about one quarter of the multinational brands, potentially making treatment more accessible to poorer patients.
The study compared one local product with its reference medicine, reporting nearly identical improvements in blood glucose and body weight. With an estimated 34.5 million adults suffering from diabetes and 110 million metabolically unwell in the country, the findings highlight the importance of affordability in diabetes treatment.
Brief written by urgent.news from Business Recorder's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
